Log in

NASDAQ:PODD - Insulet Stock Price, Forecast & News

$159.17
-6.51 (-3.93 %)
(As of 04/2/2020 02:55 AM ET)
Today's Range
$155.08
Now: $159.17
$164.77
50-Day Range
$130.01
MA: $179.60
$216.44
52-Week Range
$80.43
Now: $159.17
$219.85
Volume513,504 shs
Average Volume684,054 shs
Market Capitalization$10.01 billion
P/E Ratio884.28
Dividend YieldN/A
Beta0.76
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod. It sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, Israel, and internationally. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.
Read More
Insulet logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:PODD
CUSIP45784P10
Phone978-600-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$738.20 million
Cash Flow$0.58 per share
Book Value$1.23 per share

Profitability

Net Income$11.60 million

Miscellaneous

Employees1,350
Market Cap$10.01 billion
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive PODD News and Ratings via Email

Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter.


Insulet (NASDAQ:PODD) Frequently Asked Questions

How has Insulet's stock been impacted by COVID-19 (Coronavirus)?

Insulet's stock was trading at $172.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PODD stock has decreased by 7.5% and is now trading at $159.17. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Insulet?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 8 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Insulet.

When is Insulet's next earnings date?

Insulet is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Insulet.

How were Insulet's earnings last quarter?

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings results on Tuesday, February, 25th. The medical instruments supplier reported $0.08 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.09 by $0.01. The medical instruments supplier earned $209.40 million during the quarter, compared to analyst estimates of $197.79 million. Insulet had a net margin of 1.58% and a return on equity of 9.56%. View Insulet's earnings history.

What guidance has Insulet issued on next quarter's earnings?

Insulet issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $841.548-871.076 million, compared to the consensus revenue estimate of $879.83 million.

What price target have analysts set for PODD?

19 Wall Street analysts have issued 12 month price objectives for Insulet's shares. Their forecasts range from $100.00 to $215.00. On average, they anticipate Insulet's stock price to reach $171.50 in the next year. This suggests a possible upside of 7.7% from the stock's current price. View analysts' price targets for Insulet.

Has Insulet been receiving favorable news coverage?

Media headlines about PODD stock have been trending very negative on Thursday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Insulet earned a news sentiment score of -3.3 on InfoTrie's scale. They also gave news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutInsulet.

Who are some of Insulet's key competitors?

What other stocks do shareholders of Insulet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include Alibaba Group (BABA), Netflix (NFLX), NVIDIA (NVDA), DexCom (DXCM), salesforce.com (CRM), Roku (ROKU), Tandem Diabetes Care (TNDM), Splunk (SPLK), Veeva Systems (VEEV) and Adobe (ADBE).

Who are Insulet's key executives?

Insulet's management team includes the following people:
  • Ms. Shacey Petrovic, Pres, CEO & Director (Age 45)
  • Mr. Charles Alpuche, Exec. VP & COO (Age 59)
  • Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 47)
  • Mr. Patrick J. Sullivan, Consultant (Age 67)
  • Mr. Michael L. Levitz, Advisor (Age 45)

What is Insulet's stock symbol?

Insulet trades on the NASDAQ under the ticker symbol "PODD."

How do I buy shares of Insulet?

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Insulet's stock price today?

One share of PODD stock can currently be purchased for approximately $159.17.

How big of a company is Insulet?

Insulet has a market capitalization of $10.01 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe. View additional information about Insulet.

What is Insulet's official website?

The official website for Insulet is http://www.insulet.com/.

How can I contact Insulet?

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]


MarketBeat Community Rating for Insulet (NASDAQ PODD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  645 (Vote Outperform)
Underperform Votes:  557 (Vote Underperform)
Total Votes:  1,202
MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote "Outperform" if you believe PODD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/2/2020 by MarketBeat.com Staff

Featured Article: Equity Income

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel